- Home
- ANAB vs MNMD Comparison
ANAB vs MNMD Comparison
Compare ANAB & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- MNMD
- Stock Information
- Founded
- ANAB 2005
- MNMD 2019
- Country
- ANAB United States
- MNMD United States
- Employees
- ANAB N/A
- MNMD N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- MNMD Pharmaceuticals and Biotechnology
- Sector
- ANAB Health Care
- MNMD Health Care
- Exchange
- ANAB Nasdaq
- MNMD Nasdaq
- Market Cap
- ANAB 759.5M
- MNMD 672.1M
- IPO Year
- ANAB 2017
- MNMD N/A
- Fundamental
- Price
- ANAB $18.59
- MNMD $7.63
- Analyst Decision
- ANAB Buy
- MNMD Strong Buy
- Analyst Count
- ANAB 12
- MNMD 10
- Target Price
- ANAB $41.20
- MNMD $28.11
- AVG Volume (30 Days)
- ANAB 1.4M
- MNMD 3.1M
- Earning Date
- ANAB 03-10-2025
- MNMD 03-06-2025
- Dividend Yield
- ANAB N/A
- MNMD N/A
- EPS Growth
- ANAB N/A
- MNMD N/A
- EPS
- ANAB N/A
- MNMD N/A
- Revenue
- ANAB $57,172,000.00
- MNMD N/A
- Revenue This Year
- ANAB $229.13
- MNMD N/A
- Revenue Next Year
- ANAB N/A
- MNMD N/A
- P/E Ratio
- ANAB N/A
- MNMD N/A
- Revenue Growth
- ANAB 282.17
- MNMD N/A
- 52 Week Low
- ANAB $12.21
- MNMD $4.66
- 52 Week High
- ANAB $41.31
- MNMD $12.22
- Technical
- Relative Strength Index (RSI)
- ANAB 55.28
- MNMD 47.18
- Support Level
- ANAB $12.21
- MNMD $7.81
- Resistance Level
- ANAB $21.57
- MNMD $10.44
- Average True Range (ATR)
- ANAB 1.72
- MNMD 1.01
- MACD
- ANAB 0.39
- MNMD -0.06
- Stochastic Oscillator
- ANAB 68.16
- MNMD 29.07
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.